PRC1 and RACGAP1 are Diagnostic Biomarkers of Early HCC and PRC1 Drives Self-Renewal of Liver Cancer Stem Cells

Shixin Liao, Kaili Wang, Lulu Zhang, Gaoli Shi, Zhiwei Wang, Zhenzhen Chen, Pingping Zhu* and Qiankun He*
School of Life Sciences, Zhengzhou University, Zhengzhou, China

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths across the world. Due to the lack of reliable markers for early HCC detection, most HCC patients are diagnosed in middle/late stages. Liver cancer stem cells (CSCs), which are drivers of liver tumorigenesis, usually emerge in the early HCC stage and are also termed as liver tumor initiation cells (TIC). Liver CSCs contribute to initiation, propagation, and metastasis of HCC and also play a key role in tumor therapy. Taking advantage of online-available data sets, bioinformatic analyses, and experimental confirmation, here we have screened out PRC1 and RACGAP1 as reliable markers for early HCC detection. PRC1 or RACGAP1 knockdown dramatically inhibited the proliferation, migration, and invasion capacities of HCC cells, conferring PRC1 and RACGAP1 as predominant modulators for HCC propagation and metastasis. Moreover, the sphere formation capacity of HCC cells was impaired after PRC1 knockdown, revealing the function of PRC1 as a modulator for liver CSC self-renewal. Furthermore, the inhibitor of PRC1 had same phenotypes as PRC1 knockdown in HCC cells. Altogether, PRC1 and RACGAP1 are identified both as prognosis markers for early HCC detection and therapeutic targets for liver cancer and liver CSCs, adding additional layers for the early prognosis and therapy of HCC.

Keywords: liver cancer, cancer stem cell, self-renewal, metastasis, biomarker

INTRODUCTION

In China, the incidence of liver cancer has doubled in the past two decades. However, the HCC which accounts for 85–90% of liver cancer is still difficult to detect in the early stage using conventional tumor diagnosis methods, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasonic inspection (Roberts et al., 2018; Xie et al., 2020). The HCC patients are already in the advanced HCC stage when they are diagnosed, which largely increases the difficulty of tumor therapy and the risk of tumor-related death. In addition, due to the lack of effective means to detect the therapeutic effect, the tumor will relapse and metastasize after treatment, resulting in the death of the patient (Wu et al., 2021). Therefore, it is urgent to explore more effective methods for early diagnosis and prognostic detection of HCC.
Recently, accumulating biomarkers have been identified for tumor diagnosis and prognosis. Some tumor-specific genes are expressed in very early stages in tumorigenesis, whereas others are expressed in later stages. In addition to gene expression, gene mutation, copy number, DNA methylation, and protein levels have also been reported as biomarkers for tumor diagnosis and prognosis (Cheng et al., 2018). However, many biomarkers are obtained from limited tumor samples and thus cannot represent comprehensive features of HCC samples. With the rapid development of computer science and the rapid accumulation of biological data, bioinformatics has emerged as an efficient tool for the analysis of huge amounts of biological data. Microarray and RNA sequencing are predominant strategies in the rapid development of bioinformatics and could be used for a variety of genomics and proteomics analyses (Gao et al., 2019; Chen et al., 2020). At present, a large number of microarray data sets have been deposited in several databases, but valuable information needs to be analyzed by bioinformatics. In our study, three cohorts, namely, GSE102079, GSE112790, and GSE121248, were selected from the GEO data set for the DEG analysis as testing cohorts, and other four cohorts (GSE45267, GSE62232, GSE84402, and GSE6764) were used to confirm our results. Taking advantage of GO, KEGG, PPI, and LASSO, we finally identified PRC1, RACGAP1, CENPF, and CCNB2 as diagnosis markers of early HCC detection.

In addition to the lake of biomarkers, the significant heterogeneity of HCC also accounts for the poor prognosis of HCC patients (Zhang et al., 2019). The hierarchical organization of tumor cells within the tumor bulk is largely generated from a small subset of cells termed cancer stem cells (CSCs) (Batlle and Clevers, 2017). Liver CSCs usually emerge in the very early stage of HCC and contain several subsets (Zheng et al., 2018). With the ability of self-renewal and differentiation, liver CSCs contribute to tumor initiation, metastasis, drug resistance, and tumor relapse (Nio et al., 2017; Lee et al., 2022). Liver CSCs can survive in various clinical therapies, including chemotherapy, radiotherapy, and up-to-date immunotherapy, and differentiate into new tumors (Zheng et al., 2018). The self-renewal of liver TICs is regulated by several signaling pathways, including Wnt/β-catenin (Chen et al., 2018a), Notch (Zhu et al., 2015a), Hedgehog (Wu et al., 2019), Hippo/Yap (Guo et al., 2017), and PKC (Chen et al., 2018b) signaling pathways, which are further modulated by various intracellular and niche factors. Recently, we have identified several functional liver CSC-intrinsic factors, including C8orf4 (Zhu et al., 2015a), ZIC2 (Zhu et al., 2015b), Inc-β-Catn (Zhu et al., 2016), and cia-MAP (Chen et al., 2021). We have also proved that non-CSC secreted WNT5A drives the activation of Wnt/β-catenin signaling in liver CSCs (Chen et al., 2018a). However, the previous studies in the CSC field largely depend on a few clinical samples and many discoveries are only suitable for some patients but not for others, largely limiting the clinical applications for highly heterogenous HCC patients. Combining unbiased genome-wide screening with a large number of HCC samples and CSC detection, we have identified PRC1 and RACGAP1 as predominant modulators for HCC propagation and metastasis.

MATERIALS AND METHODS

Acquisition of Data Resources
We entered the keyword “HCC” in GEO data sets of NCBI (https://www.ncbi.nlm.nih.gov/geo/) for retrieval and got 20603 results. “Expression Profiling by Array” in the study type and “Homo Sapiens” in top organisms were added to the filters. Finally, 417 results were obtained. We selected sequencing data sets of HCC and a normal liver with a sample size greater than 100 on the same platform. Then three gene expression profiles [GSE102079 (Chiyonobu et al., 2018), GSE112790 (Shimada et al., 2019), and GSE121248 (Wang et al., 2007)] were selected. These three microarrays were based on GPL570 (HG-U133_Plus_2). The GSE102079 cohort consisted of 152 HCC samples and 91 non-cancer samples from 152 patients. The GSE112790 cohort consisted of 183 HCC samples and 15 non-cancer samples from 183 patients. The GSE121248 included 70 HCC samples and 30 normal samples from 107 patients. The basic features of GSE102079 and GSE112790 data sets have not been disclosed. The basic features of GSE121248 data sets are summarized in Table 1.

Data Analysis
GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r/) was used for the DEG analysis. We typed the number of the selected gene microarrays in GEO data sets of NCBI and clicked “analyze with GEO2R” to select HCC samples and non-cancer samples for analysis. The p value < 0.05 and |logFC| > 1.5 were used as the selection criteria.

Functional Annotation of DEGs
The GO analysis provides gene characters about cellular components (CCs), molecular functions (MFs), and biological processes (BPs). KEGG, a well-known database containing many signaling pathways, and it links the list of genes to the enrichment of signaling pathways. The DEGs could be analyzed by GO and KEGG on DAVID (https://david.ncifcrf.gov/) (Huang et al., 2009a; Huang et al., 2009b). p < 0.05 was considered to be statistically significant.

PPI Network Construction and hub Gene Identification
PPI evaluates the functional interactions between proteins through their interaction networks. The Matthews correlation coefficient (MCC), a parameter indicating correlation, can be used to screen for genes with high correlation. The Search Tool for the Retrieval of Interacting Genes (STRING) (http://string-db.org/) (Szklarczyk et al., 2021) is an online database for analysis and visualization of protein–protein interactions. We downloaded the PPI list from STRING and imported it to Cytoscape (www.cytoscape.org/); (Shannon et al., 2003) the proteins with higher MCC tend to play a more important role. cytoHubba, which could calculate MCC of each protein, is a plug-in of Cytoscape. After calculation with cytoHubba, we
TABLE 1 | Basic features of the GSE121248 data set.

| GEO accession | Tissue         | Sex | Age | HBV status |
|---------------|----------------|-----|-----|------------|
| GSM3428716    | Tumor sample   | M   | 72  | Positive   |
| GSM3428717    | Tumor sample   | M   | 39  | Positive   |
| GSM3428718    | Tumor sample   | M   | 63  | Positive   |
| GSM3428719    | Tumor sample   | M   | 44  | Positive   |
| GSM3428720    | Tumor sample   | M   | 43  | Positive   |
| GSM3428721    | Tumor sample   | M   | 38  | Positive   |
| GSM3428722    | Tumor sample   | M   | 47  | Positive   |
| GSM3428723    | Tumor sample   | F   | 74  | Positive   |
| GSM3428724    | Tumor sample   | M   | 75  | Positive   |
| GSM3428725    | Tumor sample   | F   | 58  | Positive   |
| GSM3428726    | Tumor sample   | M   | 55  | Positive   |
| GSM3428727    | Tumor sample   | M   | 51  | Positive   |
| GSM3428728    | Tumor sample   | M   | 51  | Positive   |
| GSM3428729    | Tumor sample   | M   | 67  | Positive   |
| GSM3428730    | Tumor sample   | M   | 66  | Positive   |
| GSM3428731    | Tumor sample   | M   | 67  | Positive   |
| GSM3428732    | Tumor sample   | M   | 76  | Positive   |
| GSM3428733    | Tumor sample   | M   | 50  | Positive   |
| GSM3428734    | Tumor sample   | M   | 30  | Positive   |
| GSM3428735    | Tumor sample   | M   | 54  | Positive   |
| GSM3428736    | Tumor sample   | M   | 33  | Positive   |
| GSM3428737    | Tumor sample   | M   | 61  | Positive   |
| GSM3428738    | Tumor sample   | M   | 51  | Positive   |
| GSM3428739    | Tumor sample   | M   | 38  | Positive   |
| GSM3428740    | Tumor sample   | M   | 79  | Positive   |
| GSM3428741    | Tumor sample   | M   | 68  | Positive   |
| GSM3428742    | Tumor sample   | M   | 59  | Positive   |
| GSM3428743    | Tumor sample   | M   | 72  | Positive   |
| GSM3428744    | Tumor sample   | M   | 57  | Positive   |
| GSM3428745    | Tumor sample   | F   | 52  | Positive   |
| GSM3428746    | Tumor sample   | M   | 57  | Positive   |
| GSM3428747    | Tumor sample   | F   | 35  | Positive   |
| GSM3428748    | Tumor sample   | M   | 57  | Positive   |
| GSM3428749    | Tumor sample   | M   | 33  | Positive   |
| GSM3428750    | Tumor sample   | F   | 60  | Positive   |
| GSM3428751    | Tumor sample   | M   | 69  | Positive   |
| GSM3428752    | Tumor sample   | M   | 48  | Positive   |
| GSM3428753    | Tumor sample   | M   | 75  | Positive   |
| GSM3428754    | Tumor sample   | M   | 66  | Positive   |
| GSM3428755    | Tumor sample   | M   | 59  | Positive   |
| GSM3428756    | Tumor sample   | M   | 44  | Positive   |
| GSM3428757    | Tumor sample   | M   | 66  | Positive   |
| GSM3428758    | Tumor sample   | M   | 83  | Positive   |
| GSM3428759    | Tumor sample   | M   | 64  | Positive   |
| GSM3428760    | Tumor sample   | M   | 62  | Positive   |
| GSM3428761    | Tumor sample   | M   | 73  | Positive   |
| GSM3428762    | Tumor sample   | F   | 72  | Positive   |
| GSM3428763    | Tumor sample   | M   | 39  | Positive   |
| GSM3428764    | Tumor sample   | M   | 69  | Positive   |
| GSM3428765    | Tumor sample   | M   | 35  | Positive   |
| GSM3428766    | Tumor sample   | M   | 62  | Positive   |
| GSM3428767    | Tumor sample   | M   | 59  | Positive   |
| GSM3428768    | Tumor sample   | M   | 64  | Positive   |
| GSM3428769    | Tumor sample   | M   | 70  | Positive   |
| GSM3428770    | Tumor sample   | M   | 62  | Positive   |
| GSM3428771    | Tumor sample   | M   | 56  | Positive   |
| GSM3428772    | Tumor sample   | M   | 81  | Positive   |
| GSM3428773    | Tumor sample   | M   | 77  | Positive   |
| GSM3428774    | Tumor sample   | M   | 72  | Positive   |
| GSM3428775    | Tumor sample   | F   | 74  | Positive   |
| GSM3428776    | Tumor sample   | F   | 72  | Positive   |
| GSM3428777    | Tumor sample   | M   | 64  | Positive   |
| GSM3428778    | Tumor sample   | M   | 75  | Positive   |
| GSM3428779    | Tumor sample   | M   | 51  | Positive   |

(Continued in next column)

selected the top 30 proteins with the highest MCC as hub proteins in this study.

**LASSO**

We used R version 4.0.3 to complete the lasso regression analysis, and the R package used is glmnet. LASSO (Tibshirani, 2011) regression is characterized by variable selection and regularization while fitting the generalized linear model. The degree of LASSO regression complexity adjustment is controlled by the parameter λ. The larger the parameter λ, the greater the penalty for a linear model with more variables, resulting in a model with fewer variables.

**Confirmation With Validation Cohorts**

Three gene expression profiles [GSE45267 (Chen et al., 2018c), GSE62232 (Schulze et al., 2015), and GSE84402 (Wang et al., 2017)] were selected from the GEO database.
as validation cohorts. Common DEGs and top 30 hub genes were obtained as described before. In addition, we analyzed gene expression in the normal liver, liver cirrhosis, and very early HCC tissues using the data set GSE6764 (Wurmbach et al., 2007).

Gene Expression Profiling Interactive Analysis
The gene expression profiling interactive analysis (GEPIA) (http://gipia.cancer-pku.cn/) (Tang et al., 2017), an open interactive website, could perform a personalized analysis according to user's need in expression results of RNA sequencing of 9736 tumor samples and 8587 normal samples in TCGA and GTEx databases. We performed a single gene analysis for all hub genes in 369 HCC samples and 160 normal liver samples. |log2FC| > 1; p < 0.05 was considered to be statistically significant.

Kaplan–Meier Survival Analysis of hub Genes
The Kaplan–Meier plotter (http://kmplot.com/analysis/) (Nagy et al., 2018) is a website that contains a lot of clinical characteristics about patients with 21 types of cancer (breast cancer, lung cancer, liver cancer, etc.) and could be used to assess the impact of 54K genes on survival in these cancers. In our study, the Kaplan–Meier plotter was used to analyze liver cancer survival. The hazard ratio (HR) with 95% confidence interval (CI) and log rank p value were calculated and displayed on the plot. Median is used as the cutoff criterion for the survival analysis.

DepMap
The DepMap (https://depmap.org/portal/) portal (Tsherniak et al., 2017; Dwane et al., 2021) empowers the research community to make discoveries related to cancer vulnerabilities by providing open access to key cancer dependencies using analytical and visualization tools. DepMap contains 796 CRISPR screening and 710 RNAi screening data sets, which can show the necessity of genes in various cells. By inputting PRC1, RACGAP1, CENPF, and CCNB2 into the DepMap database, the effect of knockout or knockdown genes on survival of different cell lines (including hepatoma cell lines) could be analyzed.

Immunohistochemistry
The protein expression levels of PRC1 and RACGAP1 were detected by immunohistochemistry in paraffin-embedded sections of 5-μm-thick liver cancer tissue and adjacent normal tissue, as described (Chen et al., 2016). Paraffin-embedded sections were first taken for dewaxing and antigen repair, and then the samples were incubated with PRC1 or RACGAP1 antibodies (Proteintech, #15617-1-AP, #13739-1-AP) at 4°C overnight. After incubation, the slides were cleaned with phosphate-buffered saline with Tween 20 (PBST) and incubated with HRP-conjugated secondary antibodies (Proteintech, #SA00001-2) at room temperature for 1 h. After PBST cleaning, the slides were colored with DAB (ZSGB-BIO, #ZLI-9018). Then the slides were stained with hematoxylin staining solution (solarbio, #G1080), dehydrated, and sealed with a neutral gum. Finally, the slides were observed using the SLIDEVIEW VS200 slide scanner (Olympus).

Cell Culture
Hep3B, HepG2, and HEK 293T were cultivated in Dulbecco's Modified Eagle Medium (Gibco, #12800017) containing thermally inactivated fetal bovine serum (10%) (Lonsera, #S711-001S), penicillin (100 U/ml) (Sigma), and streptomycin (Sigma) (0.1 mg/ml) under a damp 5% CO2 atmosphere at 37°C.

Gene Knockdown Vector Construction
We looked for targets on the GPP Web Portal (https://portals.broadinstitute.org/gpp/public) and designed shRNA with a fixed structure (target sequences: shPRC1-1: GCAGGGAACATCTAACAAGCATT; shPRC1-2: CCGAGTTACATGTAGAGCCAT; shRACGAP1-1: GCTAGGACGACAAGGCAACTTT; and shRACGAP1-2: GCAGGTTGAGATGAGATACAAA). shRNA primers were synthesized by BGI Tech Solutions (Beijing Liuhe). shRNA was linked to the enzyme-digestion pSicoR vector [Addgene, #11579]. The recombined plasmid was extracted using the endotoxin-free plasmid extraction kit and sequenced correctly.

Lentiviral Infection
The lentiviral gene knockdown plasmid was co-transfected into HEK293T cells with lentiviral packaging plasmids psPAX2 (Addgene, #12260) and pMD2.G (Addgene, #12259). HEK293T cells were cultivated in DMEM + 10% FBS and seeded in a 6-well cell culture plate (Corning, #3516) the day before transfection such that they would be 80–90% confluent at the time of transfection. One hour before transfection, the media was replaced with 2 ml of fresh prewarmed DMEM + 10% FBS. We added 20 μL of 2.5M CaCl2, 2 mg gene knockdown plasmid, 1.5 mg psPAX2, and 0.5 mg pMD2.G to 180 μL ddH2O. Then 200 μL HBS was added, mix thoroughly, and incubated at room temperature for 5 min. The mixture was then gently added to the 6-well cell culture plate. The transfection mix was aspirated after 8 h and replaced with fresh prewarmed DMEM + 10% FBS. Viral particles were harvested 48 h after the media was changed and filtered by a 0.22 μm syringe filter (Millipore, #SLGP033R). Liver cancer cells were cultivated in DMEM + 10% FBS and seeded in a 6-well cell culture plate the day before transfection such that they would be 50% confluent at the time of transfection. The original medium was replaced with the filtered virus fluid; polybrene (Sigma) was added at 5 mg/ml and was replaced with fresh prewarmed DMEM + 10% FBS 6 h later.

Quantitative RT-PCR
Total RNA was separated from HCC cell lines with an RNA isolator (Vazyme, #R401-01-AA), and its concentration was determined using NanoDrop ONE (Thermo Fisher Scientific). The RNA was then reverse-transcribed into cDNA using a reverse transcription kit (Vazyme, #R323-01). qRT-PCR detection was
performed using the AceQ Universal SYBR qPCR Master Mix kit (Vazyme, #Q511-02) in the QuantStudio™ 5 Real-Time PCR (Thermo Fisher Scientific) (PRC1: forward primer: CGGCATGAGGAGAAGTGG, reverse primer: TGTGAACGCCGGTGCCTCTG; RACGAP1: forward primer: AGCTTGAAAGGATGAGTCAATGGA, reverse primer: AAGTGCCCTGAGCCTAGTGG). All procedures were conducted in accordance with the manufacturer’s instructions. The thermal cycling parameters for amplification were as follows: pre-denaturation at 95°C for 10 min, denaturation at 95°C for 10 s, and annealing and extension at 60°C for 1 min for a total of 40 cycles.

**Western Blotting**

Cells were lysed in protein lysate and washed in boiling water for 15 min. Proteins were resolved in a 10% polyacrylamide gel at 80 V for 120 min and transferred to a PVDF membrane (Millipore) at 180 V for 60 min. The membrane was blocked for non-specific binding with 5% non-fat powdered milk in Tris-buffered saline with Tween 20 (TBST) for 1 h at room temperature and then probed with primary antibodies overnight at 4°C and with HRP-conjugated secondary antibodies for 1 h at room temperature. Blots were visualized with ECL detection (Meilunbio, #MA0186), and chemiluminescent signals were captured using the ChemiDoc™ MP Imaging System. Primary antibodies used were PRC1, RACGAP1, MYC-Tag (Cell Signaling Technology, #2276S), AXIN2 (Proteintech, #20540-1-AP), CCND1 (ABCAM, #AB16663), and MMP7 (Proteintech, #3801S).

**Cell Proliferation**

Hepatocarcinoma cells were isolated and seeded in 96-well plates (Corning, #353916) with 2000 cells per well. In the blank group, the medium containing FBS was added. The cells were cultured in a CO₂ cell incubator (Thermo Fisher Scientific) for 24, 48, 72, and 96 h. Before testing, each well was changed into working solution (medium 100 fi version 10.5.3. platform, and results were analyzed using FlowJo software version 10.5.3.

**Flow Cytometry**

We collected the cells and washed them with PBS. Then the cells were fixed with a fixation/permeabilization concentrate (Thermo Fisher Scientific, #00-5123-43) at 4°C for 0.5 h and permeated with a permeabilization buffer (Thermo Fisher Scientific, #00-8333-56) at 4°C for 5 min. Then the cells were incubated with Ki-67 APC direct-labeled antibody (Thermo Fisher Scientific, #17-5699-42) at room temperature for 20 min and washed with PBS. Flow cytometry was performed on the FACSymphony™-S6 (BD Biosciences) platform, and results were analyzed using FlowJo software version 10.5.3.

**Immunofluorescence**

Immunofluorescence was used to detect the expression level of Ki-67 in HCC cell slides to indicate cell proliferation ability. First, liver cancer cells were inoculated on the slides and fixed with 4% paraformaldehyde (Biosharp, #BL539A). The slides were then cleaned with PBS and incubated with the Ki-67 APC direct-labeled antibody at room temperature for 1 h. After cleaning with PBS, the sample was sealed with an antifading mounting medium (with DAPI) (Solarbio, #S2110). Finally, the slides were observed using the SLIDEVIEW VS200 slide scanner (Olympus).

**Colony Formation Assay**

Hepatocarcinoma cells were isolated and seeded in 6-well plates with 500 cells per well. After being cultured for 10 days, cell specimens in PBS were collected and fixed with 4% paraformaldehyde before being subjected to crystal violet staining (Solarbio, #G1062). The clone (>50 cells) number was measured using a scanner.

**Wound-Healing Assay**

Confluent cells were scraped using a 10 μL pipette tip (Axygen, #AXYT300). After 24 h, the cells migrated to the wound and the scratched area were examined using an inverted microscope (Nikon, ECLIPSE Ti2). The migration rate was obtained by the formula: (Width0h−Width24h)/Width0h.

**Transwell**

For the cell migration assay, the density of HCC cells was adjusted to 1 × 10⁵ cells/mL by using DMEM without FBS. We placed the Transwell permeable supports (Corning, #3422) into the 24-well plate (Corning, #3524), and added 600 μL DMEM containing 10% FBS to the lower chamber and 200 μL cell fluid to the upper chamber. After 24 h, the cells were fixed with 4% paraformaldehyde and stained with crystal violet. Finally, the cell was photographed using an inverted microscope.

For the cell invasion assay, serum-free DMEM was mixed with Matrigel (Corning, #354320) in 8:1 and evenly spread in the upper chamber of Transwell permeable supports. The chambers were then placed in a cell incubator for 30 min to solidify the Matrigel. Other operations were the same as the cell migration experiment.

**Sphere Formation Assay**

A sphere formation assay was performed, as described (Chen et al., 2018d). In brief, hepatocarcinoma cells were seeded in ultra-low attachment 6-well plates (Corning, #3471) and cultured in Dulbecco’s Modified Eagle’s Medium/F12 (Gibco, #1130032) supplemented with B27 (Thermo Fisher Scientific, #17504044), N2 (Thermo Fisher Scientific, #17502048), 20 ng/ml epidermal growth factor (Thermo Fisher Scientific), and 20 ng/ml basic fibroblast growth factor (Thermo Fisher Scientific). Cells were incubated in a CO₂ incubator, and 3 days later spheres were counted using an inverted microscope.

**Statistics**

Statistical significance was evaluated using a two-tailed Student’s t test. p values <0.05 were considered significant.
FIGURE 1 | Bioinformatic screening of HCC hub genes. (A) Volcanic maps of differentially expressed genes in HCC in GSE102079, GSE112790, and GSE121248 data sets. The \( p \) value < 0.05 and |logFC| > 1.5 were used as the selection criteria. (B) Venn plots of differentially expressed genes in GSE102079, GSE112790, and GSE121248 data sets. (C) GO analysis of common differentially expressed genes. (D) KEGG analysis of common differentially expressed genes. (E) Protein–protein interaction networks of differentially expressed genes. (F) Top 30 hub genes were screened by MCC. The color of the circle represents the number of proteins that interacts with it.
FIGURE 2 | Validation of hub genes in HCC. (A,B) PRC1, RACGAP1, CENPF, and CCNB2 were screened by LASSO. (C) In the GEPIA database, high expression of PRC1, RACGAP1, CENPF, and CCNB2 in HCC was verified. (D) Overexpression of PRC1, RACGAP1, CENPF, and CCNB2 is associated with poor OS in HCC patients. (E) Compared with normal tissues, PRC1, RACGAP1, CENPF, and CCNB2 were overexpressed in very early HCC samples, but there was no significant difference in cirrhosis samples. (F) PRC1 and RACGAP1 were shown as essential genes in the DepMap database. (G) Quantitative immunohistochemical study of PRC1 and RACGAP1 in HCC and normal liver tissues. Scale bars, overall plots, 1 mm, local plots, 100 μm. ns, p ≥ 0.05; ***p < 0.001, data are shown as mean ± s.d.
FIGURE 3 | PRC1 and RACGAP1 drive the propagation of liver cancer. (A,B) (A) Two thousand Hep3B or HepG2 cells with PRC1 or RACGAP1 knockdown and (B) two thousand Hep3B or HepG2 cells treated with 10 μM PRT4165 or DMSO were seeded in 96-well plates and detected by CCK-8 at 6, 24, 48, 72, and 96 h, respectively. The cell proliferation rate was denoted by OD450. (C,D) (C) 1 × 10⁴ PRC1 or RACGAP1 depleted Hep3B (upper panels) and HepG2 (lower panels) cells; (D) 1 × 10⁴ Hep3B (upper panels) and HepG2 (lower panels) cells added 10 μM PRT4165 or DMSO were used for intracellular staining for Ki-67. (E,G) (E) 1 × 10⁵ PRC1 or RACGAP1 depleted Hep3B (upper panels) and HepG2 (lower panels) cells; (G) 1 × 10⁵ Hep3B (upper panels) and HepG2 (lower panels) cells added 10 μM PRT4165 (Continued)
Study Approval
Human liver cancer specimens were obtained from the Department of Hepatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University with informed consent, according to the Institutional Review Board approval.

RESULTS
Bioinformatics Screening of Hepatocellular Carcinoma hub Genes
To screen DEGs between HCC and non-tumor tissues, three cohorts (GSE102079, GSE112790, and GSE121248) were selected for further analysis. From GSE102079, GSE112790, and GSE121248, 580 DEGs (163 upregulated and 417 downregulated), 948 DEGs (355 upregulated and 593 downregulated), and 462 DEGs (123 upregulated and 339 downregulated) were screened, respectively (Figure 1F). The intersection of DEGs in three data sets was further visualized using the Venn map (https://bioinfogp.cnb.csc.es/tools/venny/index.html). Finally, 268 common DEGs were identified, including 84 upregulated and 184 downregulated genes (Figure 1B).

GO and KEGG analyses of DEGs were performed on DAVID. As shown in Figure 2C, upregulated BPs mainly include cell division, mitotic nuclear division, and sister chromatid cohesion, while downregulated BPs mainly include the oxidation–reduction process, immune response, and xenobiotic metabolic process; upregulated CCs mainly include nucleus, cytoplasm, cytosol, and nucleoplasm, and downregulated CCs mainly include extracellular exosome, extracellular region, extracellular space, and endoplasmic reticulum membrane; upregulated MFs are protein binding and microtubule binding, and downregulated MFs show the protein homodimerization activity, heme binding, and iron ion binding. In addition, the upregulated DEGs were related to three KEGG pathways, including cell cycle, oocyte meiosis, and progesterone-mediated oocyte maturation, while the downregulated genes were significantly enriched in metabolic pathways, retinol metabolism, and chemical carcinogenesis (Figure 1D).

In order to investigate the function of these genes, a PPI network with 123 nodes and 516 edges was constructed using cytoscape. These 123 nodes and 516 edges represent 123 proteins and 516 PPI, respectively. Then top 30 hub proteins were filtered out using cytoHubba plug-in of cytoscape. Interestingly, these hub genes are all upregulated DEGs, indicating their predominant oncogenic role in liver tumorigenesis.

Validation of hub Genes in Hepatocellular Carcinoma
A total of 30 hub genes were analyzed by LASSO, and four target genes were further screened: PRC1, RACGAP1, CENPF, and CCNB2 (Figures 2A,B). All these four genes were included in the top 30 Hub genes of the validation cohorts (GSE45267, GSE62232, and GSE84402) (Supplementary Figure S1A), and the high expression of these four genes in HCC was also confirmed in the GEPIA database (Figure 2C). Subsequently, a survival analysis of these four hub genes was carried out with the Kaplan–Meier plotter, and the overexpression of them was significantly associated with poor survival in HCC patients (Figure 2D). Part of the occurrence of HCC is associated with further deterioration of liver cirrhosis. We analyzed the expression of these four genes in a normal liver, liver cirrhosis, and very early HCC tissues with data set GSE6764, and the results showed that these four genes were highly expressed in very early HCC tissues but not in liver cirrhosis (Figure 2E). This study revealed that PRC1, RACGAP1, CENPF, and CCNB2 could sensitively distinguish HCC from cirrhosis, and they may be potential targets for early HCC detection. In the DepMap database, we analyzed the importance of these four genes in cell survival, and the results showed that PRC1 and RACGAP1 are common essential genes in cell survival, including liver cancer cells (Figure 2F). Subsequently, the high expression of PRC1 and RACGAP1 in HCC was further verified by immunohistochemical results of HCC samples and normal adjacent liver samples (Figure 2G).

PRC1 and RACGAP1 Drive the Propagation of Liver Cancer
In order to verify the function of PRC1 and RACGAP1 in HCC cells, we designed two shRNAs for each of these two genes, and constructed PRC1 knockdown and RACGAP1 knockdown cells using Hep3B and HepG2 cell lines. Both genes were significantly silenced in the corresponding knockdown cell lines (Supplementary Figures S1B,C), which showed an impaired proliferation capacity (Figure 3A). PRT4165 is an inhibitor of PRC1 (Ismail et al., 2013), and the propagation ability of HCC cells treated by PRT4165 was also significantly reduced (Figure 3B). We labeled the cells with Ki-67 antibody indicating cell proliferation and detected them by flow cytometry and immunofluorescence (Figures 3C,E). It was confirmed that PRC1 and RACGAP1 promoted proliferation. We also performed the clone formation assay and found a decreased clone formation capacity on PRC1, RACGAP1 knockdown, and PRT4165 treatment (Figures 3F,H). Cells treated with PRT4165 showed the same phenotypic changes (Figures 3D,G). These data suggest that PRC1 and RACGAP1 promote the growth and proliferation of liver cancer.

PRC1 and RACGAP1 Increase the Metastasis of Liver Cancer
We also detected the role of PRC1 and RACGAP1 in tumor metastasis. The wound-healing assay revealed that PRC1,
FIGURE 4 | PRC1 and RACGAP1 increase the metastasis of liver cancer. (A,B) 1 × 10^5 PRC1 or RAPGAP1 knockdown Hep3B (upper panels) and HepG2 (lower panels) cells; (B) 1 × 10^5 Hep3B (upper panels) and HepG2 (lower panels) cells treated with 10 μM PRT4165 or DMSO were seeded in 24-well plates. The cells were scratched with 10 μL tips and photographed at 0 and 24 h. The migration rate was obtained by the formula: (Width_0h − Width_24h)/Width_0h. (C,E) 2 × 10^4 PRC1 or RAPGAP1 knockdown Hep3B (upper panels) and HepG2 (lower panels) cells; (E) 2 × 10^4 Hep3B (upper panels) and HepG2 (lower panels) cells treated with 10 μM PRT4165 or DMSO were seeded to the upper chamber and stained with crystal violet after 24 h. (D,F) 2 × 10^4 PRC1 or RAPGAP1 knockdown Hep3B (upper panels) and HepG2 (lower panels) cells; (F) 2 × 10^4 Hep3B (upper panels) and HepG2 (lower panels) cells treated with 10 μM PRT4165 or DMSO were seeded to the upper chamber treated with Matrigel and stained with crystal violet after 24 h. Scale bars, 100 μm. ***p < 0.001, data are shown as mean ± s.d. Data are representative of at least three independent experiments.
FIGURE 5 | PRC1 promotes the self-renewal of liver CSCs through Wnt signaling. (A) High expression of PRC1 and RACGAP1 in liver CSCs was detected by Western blot. (B,C) 2 × 10^4 PRC1 or RAPGAP1 knockdown Hep3B (upper panels) and HepG2 (lower panels) cells; (C) 2 × 10^4 Hep3B (upper panels) and HepG2 (lower panels) cells treated with 10 μM PRT4165 or DMSO were seeded in ultra-low attachment 6-well plates and cultured in Dulbecco’s Modified Eagle’s Medium/F12 supplemented with B27, N2, 20 ng/ml epidermal growth factor, and 20 ng/ml basic fibroblast growth factor. After three days, the spheres were examined under a microscope. (D,E) qRT-PCR was used to verify the mRNA expression of AXIN2, MYC, CCND1, and MMP7. (F,G) Protein level expression of AXIN2, C-MYC, CCND1, and MMP7 was verified by Western blot. Scale bars: 100 μm.  ns p ≥ 0.05; ***p < 0.001, data are shown as mean ± s.d. Data are representative of at least three independent experiments.
RACGAP1 silencing, and PRT4165 treatment significantly decreased the cell metastasis rate (Figures 4A,B). We also found that PRC1 or RACGAP1 depletion dramatically reduced the migration and invasion of Hep3B and HepG2 cells with Transwell assays (Figures 4C–F). Therefore, these data suggest that PRC1 and RACGAP1 increased metastasis of liver cancer.

**PRC1 Promotes the Self-Renewal of Liver CSCs Through Wnt Signaling**

PRC1 and RACGAP1 are highly expressed in liver CSCs (Figure 5A), so we then detected whether PRC1 and RACGAP1 play a critical role in the stemness of Hep3B and HepG2 cells using the sphere formation assay. The results showed that PRC1 knockdown or PRT4165 treatment significantly reduced the sphere formation capacity of Hep3B and HepG2 cells, while RACGAP1 did not (Figures 5B,C). Therefore, PRC1 can enhance the stemness of Hep3B and HepG2 cells.

It has been reported that PRC1 promotes the self-renewal ability of lung CSCs through the WNT signaling pathway (Zhan et al., 2017). We detected mRNA and protein expression levels of WNT target genes AXIN2, MYC, CCND1, and MMP7 and found that they were significantly reduced in liver CSCs with PRC1 knockdown and PRT4165 treatment (Figures 5D–G). It is revealed that PRC1 promotes the self-renewal of liver CSCs through the Wnt signaling pathway.

**DISCUSSION**

As a predominant type of liver cancer, HCC has a very high cancer mortality rate, which is mainly due to tumor heterogeneity and lack of early diagnosis. HCC patients are generally in an advanced HCC stage when they are detected and thus miss the best time of therapy (Llovet et al., 2018). In addition, some HCC patients have tumor recurrence or metastasis resulting in death due to lack of appropriate prognostic detection methods after treatment (Wang et al., 2017). Therefore, it is important to find more accurate and reliable biomarkers for the diagnosis and prognosis of HCC. In this study, we selected three HCC data sets from the GEO database and used the GEO2R online analysis to obtain the differential genes between HCC and non-cancer samples. Next, we constructed a PPI network and screened the top 30 hub genes from 268 DEGs. These 30 genes were enriched by LASSO regression and analyzed in the DepMap database, and PRC1 and RACGAP1 were finally screened out as potential targets for early HCC detection. Subsequently, the high expression of PRC1 and RACGAP1 in HCC was verified by immunohistochemistry. We constructed HCC cell lines with PRC1 or RACGAP1 knockdown and performed cell proliferation, metastasis, and stemness experiments, which revealed that PRC1 and RACGAP1 enhanced the propagation and metastasis of HCC. In addition, PRC1
promoted the self-renewal ability of liver CSCs through the WNT signaling pathway (Figure 6).

Taking advantage of the bioinformatic analysis and functional validation, we have identified PRC1 and RACGAP1 as diagnosis markers and therapeutic targets in this study. The polycomb repressive system plays a fundamental role in controlling gene expression during mammalian development (Blackledge et al., 2020). To achieve this, polycomb repressive complexes 1 and 2 (PRC1 and PRC2) bind target genes and use histone modification-dependent feedback mechanisms to form polycomb chromatin domains and repress transcription (Fursova et al., 2019). PRC1 is an E3 ubiquitin ligase that mono-ubiquitylates histone H2A at lysine 119 (H2AK119ub1), which is regulator of gene expression required for embryonic stem cell (ESC) fate decisions during development (Tamburri et al., 2020). PRC1 also affects the function of certain types of adult stem cells, and their misregulation contributes to tumorigenesis in several tissues (Jia et al., 2021). Rac GTPase activation protein 1 (RACGAP1) is a component of the centrosomal complex that serves as a microtubule-dependent and Rho-mediated signaling required for the myosin contractile ring formation during the cell cycle cytokinesis (Wang et al., 2019). RACGAP1 was initially identified in testis and male germ cells and has been demonstrated to be a key regulator in various malignancies, such as colorectal cancer (Zhou et al., 2018), ovarian cancer (Wang et al., 2018), meningioma (Ke et al., 2013), uterine cancer (Ebinger et al., 2016), and breast cancer (Ren et al., 2021). In addition, RACGAP1 plays a critical role in mitochondrial fission and speeds up mitochondrial renewal and mitochondrial respiration, which leads to cancer cell metastasis (Zhou et al., 2021).

In past studies, some diagnostic biomarkers for HCC have been found using bioinformatic analyses and experimental verifications. But they are difficult to be transformed into clinical diagnosis and treatment due to their inability to distinguish liver lesions from cancer (De Stefano et al., 2018). According to our experimental results, PRC1 and RACGAP1 are highly expressed in early HCC, while there is no significant difference between normal liver tissues and cirrhotic tissues, which suggests that PRC1 and RACGAP1 have high sensitivity and reliability as biomarkers for early HCC diagnosis. After surgical removal of the tumor, there is still about a 70% chance of recurrence and metastasis, resulting in death of HCC patients (Xu et al., 2019). Our results indicate that PRC1 and RACGAP1 can promote the proliferation and metastasis of HCC. It provides potential targets for controlling the progression of HCC and inhibiting metastasis, which is of great significance for the treatment of HCC and improving the prognosis of patients.

In CSC theory, tumor growth is caused by the continuous proliferation of a class of stem cells, CSCs, similar to normal tissue renewal (Shimokawa et al., 2017; Toh et al., 2017; Chen et al., 2021). It suggests that HCC treatment should not only reduce tumor size but also inhibit the growth of liver CSCs. We found that PRC1 promoted the self-renewal ability of liver CSCs, which is exciting for inhibiting the growth of liver CSCs and improving the therapeutic effect of HCC. Our results also confirmed that PRC1 increases the self-renewal ability of liver CSCs through the WNT signaling pathway, closely related to stemness, which further proved that PRC1 is a reliable therapeutic target for HCC.

In conclusion, PRC1 and RACGAP1 screened by the bioinformatic analysis and experimental verification can promote the proliferation and metastasis of HCC, and PRC1 also improves the self-renewal ability of liver CSCs. Therefore, PRC1 and RACGAP1 are identified as prognosis markers for early HCC and therapeutic targets for liver cancer and liver CSCs.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

SL designed and performed experiments, analyzed data, and wrote the manuscript. KW and GS performed LASSO. LZ, ZW and ZC analyzed data. PZ and QH initiated the study and designed experiments. SL, PZ and QH edited the manuscript.

FUNDING

This work was supported by the Ministry of Science and Technology of the People’s Republic of China (2020YFA0803500) and National Natural Science Foundation of China (31922024).

ACKNOWLEDGMENTS

The authors thank all individuals who contributed to sample information and research personnel responsible for data acquisition. Data are available on the GEO database. We thank the supporting grants from Zhengzhou University to PZ, and the technical support from Modern Analysis and Computer Center of Zhengzhou University.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2022.864051/full#supplementary-material

Supplementary Figure S1 | (A) PRC1, RACGAP1, CENPF, and CCNB2 were included in the TOP 30 hub genes of the validation group (GSE45267, GSE62232, and GSE84402). The color of the circle represents the number of proteins that interact with it. (B, C) Knockdown efficiency of PRC1 and RACGAP1 in Hep3B and HepG2 cells. In (B) detected by qRT-PCR and in (C) detected by Western blot. ***p < 0.001, data are shown as mean ± s.d.
REFERENCES

Battle, E., and Clevers, H. (2017). Cancer Stem Cells Revisited. Nat. Med. 23, 1124–1134. doi:10.1038/nmm.4409

Blackledge, N. P., Fursova, N. A., Kelley, J. R., Huseyin, M. K., Feldmann, A., and Klose, R. J. (2020). PRC1 Catalytic Activity Is Central to Polycytoplasmic System Function. Mol. Cell. 77, 857–874. doi:10.1016/j.molcel.2019.12.001

Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., and Chen, X. (2020). Harnessing Big ‘omics’ Data and AI for Drug Discovery in Hepatocellular Carcinoma. Nat. Rev. Gastroenterol. Hepatol. 17, 238–251. doi:10.1038/s41575-019-0240-9

Chen, C. L., Tai, Y. S., Huang, Y. H., Liang, Y. J., Sun, Y. Y., Su, C. W., et al. (2018). Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression through Transcriptional Regulation of Epithelial-Mesenchymal Transition Regulators and Stemness Genes. Hepatol. Commun. 2, 1392–1407. doi:10.1002/hep.1229

Chen, Z.-z., Huang, L., Wu, Y.-h., Zhai, W.-j., Zhu, P.-p., and Gao, Y.-f. (2016). Integrative Analysis through Transcriptional Regulation of Epithelial-Mesenchymal Transition Regulators and Stemness Genes. Ncomms12598.

Cheng, J., Wei, D., Ji, Y., Chen, L., Yang, L., Li, G., et al. (2018). Integrative Analysis of DNA Methylation and Gene Expression Reveals Hepatocellular Carcinoma-specific Diagnostic Biomarkers. Genome Med. 10, 42. doi:10.1186/s13073-018-0548-x

Chiyonobu, N., Shimada, S., Akiyama, Y., Mogushi, K., Itoh, M., Akahoshi, K., et al. (2018). Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors. Am. J. Pathol. 188, 1213–1224. doi:10.1016/j.ajpath.2018.01.012

De Stefano, F., Chacon, E., Turcios, L., Marti, F., and Gedaly, R. (2018). Novel Biomarkers in Hepatocellular Carcinoma. Dig. Liver Dis. 50, 1115–1123. doi:10.1016/j.dld.2018.08.019

Dwane, L., Behan, F. M., Gonçalves, E., Lightfoot, H., Yang, W., van der Meer, D., et al. (2021). Project Score Database: a Resource for Investigating Cancer Cell Signaling at DNA Double-Strand Breaks. J. Biol. Chem. 298, 26944–26954. doi:10.1074/jbc.m121.461699

Jia, Y., Ding, X., Zhou, L., Zhang, L., and Yang, X. (2021). Mesenchymal Stem Cells-Derived Exosomal microRNA-139-5p Restrains Tumorigenesis in Bladder Cancer by Targeting PRC1. Oncogene 40, 246–261. doi:10.1038/s41388-020-01486-7

Ke, H.-L., Ke, R.-H., Li, S.-T., Li, B., Lu, H.-T., and Wang, X.-Q. (2013). Expression of RACGAP1 in High Grade Meningiomas: a Potential Role in Cancer Progression. J. Neurooncol. 113, 327–332. doi:10.1007/s10663-011-1211-7

Lee, T.-K., Wu, G.-Y., and Ma, S. (2022). Cancer Stem Cells in Hepatocellular Carcinoma - from Origin to Clinical Implications. Nat. Rev. Gastroenterol. Hepatol gastroenterology Hepatology 19, 26–44. doi:10.1038/s41575-021-00508-3

Llovet, J. M., Montal, R., Sia, D., and Finn, R. S. (2018). Molecular Therapies and Precision Medicine for Hepatocellular Carcinoma. Nat. Rev. Oncol. 15, 599–616. doi:10.1038/nr0171-00073-4

Nagy, A., Lánczyk, A., Menyhért, O., and Győrfy, B. (2018). Validation of miRNA Prognostic Power in Hepatocellular Carcinoma Using Expression Data of Independent Datasets. Sci. Rep. 8, 9227. doi:10.1038/s41598-018-27521-y

Nio, K., Yamashita, T., and Kaneko, S. (2017). The Evolving Concept of Liver Cancer Stem Cells. Mol. Cancer 16, 4. doi:10.1186/s12943-016-0572-9

Ren, K., Zhou, D., Wang, M., Li, E., Hou, C., Su, Y., et al. (2021). RACGAP1 Modulates EC2-dependent Mitochondrial Quality Control to Drive Breast Cancer Metastasis. Exp. Cell Res. 400, 112493. doi:10.1016/j.yexcr.2021.112493

Roberts, L. R., Sirlin, C. B., Almasri, J., Prokop, L. J., Heimbach, J. K., et al. (2018). Imaging for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Hepatology 67, 401–421. doi:10.1002/hep.29487

Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderero, J., Rebouissou, S., et al. (2015). Exome Sequencing of Hepatocellular Carcinomas Identifies New Mutational Signatures and Potential Therapeutic Targets. Nat. Genet. 47, 505–511. doi:10.1038/ng.3252

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramu, D., et al. (2003). Cytoscape: a Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 13, 2498–2504. doi:10.1101/gr.129303

Shimada, S., Mogushi, K., Akiyama, Y., Furuyama, T., Watanabe, S., Ogura, T., et al. (2021). Comprehensive Molecular and Immunological Characterization of Hepatocellular Carcinoma. Ebiomedi ce 40, 457–470. doi:10.1016/j.ebiom.2018.12.058

Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., et al. (2017). Visualization and Targeting of LGR5+ Human colon Cancer Stem Cells. Nature 545, 187–192. doi:10.1038/nature22081

Szkarlaczzyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., et al. (2019). Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. Cancer Cell 30, 849–862. doi:10.1016/j.ccell.2016.11.002

Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., et al. (2019). Comprehensive Molecular and Immunological Characterization of Hepatocellular Carcinoma. Ebiomedi ce 40, 457–470. doi:10.1016/j.ebiom.2018.12.058

Tamburri, S., Lavarone, E., Fernandez-Perez, D., Conway, E., Zanotti, M., Manarano, D., et al. (2020). Histone H2AK119 Mono-Ubiquitination Is Essential for Polycomb-Mediated Transcriptional Repression. Mol. Cell. 77, 840–856. doi:10.1016/j.molcel.2019.11.021

Tang, Z., Li, C., Kang, B., Gao, G., Li, C., and Zhang, Z. (2017). GEPIA: a Web Server for Cancer and normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Res. 45, W98–w102. doi:10.1093/nar/gkw247

Tibshirani, R. (2011). Regression Shrinkage and Selection via the Lasso. J. R. Stat. Soc. Ser. B (Statistical Methodology) 73, 273–282. doi:10.1111/j.1467-9868.2011.00771.x

Toh, T. B., Lim, J. I., and Chow, E. K.-H. (2017). Epigenetics in Cancer Stem Cells. Mol. Cancer 16, 29. doi:10.1186/s12943-017-0596-9

Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., et al. (2017). Defining a Cancer Dependency Map. Cell 170, 564–576. doi:10.1016/j.cell.2017.06.010
Wang, C., Wang, W., Liu, Y., Yong, M., Yang, Y., and Zhou, H. (2018). Rac GTPase Activating Protein 1 Promotes Oncogenic Progression of Epithelial Ovarian Cancer. Cancer Sci. 109, 84–93. doi:10.1111/cas.13434

Wang, H., Huo, X., Yang, X.-R., He, J., Cheng, L., Wang, N., et al. (2017). STAT3-mediated Upregulation of IncRNA HOXD-AS1 as a ceRNA Facilitates Liver Metastasis by Regulating SOX4. Mol. Cancer 16, 136. doi:10.1186/s12943-017-0680-1

Wang, M.-Y., Chen, D.-P., Qi, B., Li, M.-Y., Zhu, Y.-Y., Yin, W.-J., et al. (2019). Pseudogene RACGAP1P Activates RACGAP1/Rho/ERK Signalling axis as a Competing Endogenous RNA to Promote Hepatocellular Carcinoma Early Recurrence. Cell Death Dis 10, 426. doi:10.1038/s41419-019-1666-2

Wang, S. M., Ooi, L. P. J., and Hui, K. M. (2007). Identification and Validation of a Novel Gene Signature Associated with the Recurrence of Human Hepatocellular Carcinoma. Clin. Cancer Res. 13, 6275–6283. doi:10.1158/1078-0432.ccrr-06-2236

Wu, J., Gao, W., Tang, Q., Yu, Y., You, W., Wu, Z., et al. (2021). Retracted: M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring α Mβ 2 Integrin to Tumor Cells. Hepatology 73, 1365–1380. doi:10.1002/hep.31432

Wu, J., Zhu, P., Lu, T., Du, Y., Wang, Y., He, L., et al. (2019). The Long Non-coding RNA LncHDAC2 Drives the Self-Renewal of Liver Cancer Stem Cells via Activation of Hedgehog Signaling. J. Hepatol. 70, 918–929. doi:10.1016/j.jhep.2018.12.015

Wurmbach, E., Chen, Y.-b., Khitrov, G., Zhang, W., Roayaei, S., Schwartz, M., et al. (2007). Genome-wide Molecular Profiles of HCV-Induced Dysplasia and Hepatocellular Carcinoma. Hepatology 45, 938–947. doi:10.1002/hep.21622

Xie, D. Y., Ren, Z. G., Zhou, J., Fan, J., and Gao, Q. (2020). 2019 Chinese Clinical Guidelines for the Management of Hepatocellular Carcinoma: Updates and Insights. Hepatobiliary Surg. Nutr. 9, 452–463. doi:10.21037/hbsn-20-480

Xu, X.-F., Xing, H., Han, J., Li, Z.-L., Lau, W.-Y., Zhou, Y.-H., et al. (2019). Risk Factors, Patterns, and Outcomes of Late Recurrence after Liver Resection for Hepatocellular Carcinoma. JAMA Surg. 154, 209–217. doi:10.1001/jamasurg.2018.4334

Zhan, P., Zhang, B., Xi, G.-m., Wu, Y., Liu, H.-b., Liu, Y.-f., et al. (2017). PRC1 Contributes to Tumorigenesis of Lung Adenocarcinoma in Association with the Wnt/β-Catenin Signaling Pathway. Mol. Cancer 16, 108. doi:10.1186/s12943-017-0682-z

Zhang, Q., Lou, Y., Yang, J., Wang, J., Feng, J., Zhao, Y., et al. (2019). Integrated Multiomic Analysis Reveals Comprehensive Tumour Heterogeneity and Novel Immunophenotypic Classification in Hepatocellular Carcinomas. Gut 68, 2019–2031. doi:10.1136/gutjnl-2019-318912

Zheng, H., Pomyen, Y., Hernandez, M. O., Li, C., Livak, F., Tang, W., et al. (2018). Single-cell Analysis Reveals Cancer Stem Cell Heterogeneity in Hepatocellular Carcinoma. Hepatology 67, 127–140. doi:10.1002/hep.29778

Zhou, D., Ren, K., Wang, M., Wang, J., Li, E., Hou, C., et al. (2021). Long Non-coding RNA RACGAP1P Promotes Breast Cancer Invasion and Metastasis via miR-345-5p/RACGAP1-mediated Mitochondrial Fission. Mol. Oncol. 15, 543–559. doi:10.1002/1878-0261.12866

Zhou, Z., Cheng, Y., Jiang, Y., Liu, S., Zhang, M., Liu, J., et al. (2018). Ten Hub Genes Associated with Progression and Prognosis of Pancreatic Carcinoma Identified by Co-expression Analysis. Int. J. Biol. Sci. 14, 124–136. doi:10.7150/ijbs.22619

Zhu, P., Wang, Y., Du, Y., He, L., Huang, G., Zhang, G., et al. (2015). C8orf4 Negatively Regulates Self-Renewal of Liver Cancer Stem Cells via Suppression of NOTCH2 Signalling. Nat. Commun. 6, 7122. doi:10.1038/ncomms8122

Zhu, P., Wang, Y., He, L., Huang, G., Du, Y., Zhang, G., et al. (2015). ZIC2-dependent OCT4 Activation Drives Self-Renewal of Human Liver Cancer Stem Cells. J. Clin. Invest. 125, 3795–3808. doi:10.1172/jci81979

Zhu, P., Wang, Y., Huang, G., Ye, B., Liu, B., Wu, J., et al. (2016). Lnc-β-Catm Elicits EZH2-dependent β-catenin Stabilization and Sustains Liver CSC Self-Renewal. Nat. Struct. Mol. Biol. 23, 631–639. doi:10.1038/nsmb.3235

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liao, Wang, Zhang, Shi, Wang, Chen, Zhu and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.